dc.creator | Perdomo, Carolina | es |
dc.creator | D'Ingianna, Paola | es |
dc.creator | Escalada, Javier | es |
dc.creator | Petta, Salvatore | es |
dc.creator | Romero Gómez, Manuel | es |
dc.creator | Ampuero Herrojo, Javier | es |
dc.date.accessioned | 2023-07-11T08:00:45Z | |
dc.date.available | 2023-07-11T08:00:45Z | |
dc.date.issued | 2020 | |
dc.identifier.citation | Perdomo, C., D'Ingianna, P., Escalada, J., Petta, S., Romero Gómez, M. y Ampuero Herrojo, J. (2020). Nonalcoholic fatty liver disease and the risk of metabolic comorbidities: how to manage in clinical practice. Polish archives of internal medicine, 130 (11), 975-985. https://doi.org/10.20452/pamw.15510. | |
dc.identifier.issn | 1897-9483 | es |
dc.identifier.uri | https://hdl.handle.net/11441/147836 | |
dc.description.abstract | Nonalcoholic fatty liver disease (NAFLD) is a clinical condition that encompasses various forms of liver damage not caused by chronic alcohol consumption. In the absence of other etiologies, it ranges from steatosis to nonalcoholic steatohepatitis and cirrhosis. The prevalence of NAFLD has considerably increased over the last years owing to the current lifestyle (unhealthy diet and sedentarism). Besides, it is associated with metabolic risk factors such as obesity, arterial hypertension, dyslipidemia, and type 2 diabetes. Given the poor prognosis of patients with advanced NAFLD, a practical therapeutic approach is necessary to halt its natural history. However, no licensed drugs have been approved for this purpose to date. Nowadays, we are in a race to find the first drug able to stop the incidence of NAFLD and reverse the disease in patients at more advanced stages. Meanwhile, the management of the NAFLD metabolic overload, including weight loss, cardiovascular protection, insulin sensitization, and lipid reduction, is the only strategy to improve hepatic and extrahepatic outcomes. In this review, we aimed to describe the management of the main metabolic disorders related to NAFLD, such as type 2 diabetes, arterial hypertension, and dyslipidemia. | es |
dc.format | application/pdf | es |
dc.format.extent | 11 pág. | es |
dc.language.iso | eng | es |
dc.publisher | Medycyna Praktyczna | es |
dc.relation.ispartof | Polish archives of internal medicine, 130 (11), 975-985. | |
dc.rights | Atribución-NoComercial-CompartirIgual 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/ | * |
dc.subject | Arterial hypertension | es |
dc.subject | Dyslipidemia | es |
dc.subject | Nonalcoholic fatty liver disease | es |
dc.subject | Type 2 diabetes | es |
dc.title | Nonalcoholic fatty liver disease and the risk of metabolic comorbidities: how to manage in clinical practice | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.projectID | PI--0075--2014 | es |
dc.relation.projectID | PI19/01404; PI16/01842; PI17/00535; GLD19/00100 | es |
dc.relation.publisherversion | https://www.mp.pl/paim/issue/article/15510/ | es |
dc.identifier.doi | 10.20452/pamw.15510 | es |
dc.journaltitle | Polish archives of internal medicine | es |
dc.publication.volumen | 130 | es |
dc.publication.issue | 11 | es |
dc.publication.initialPage | 975 | es |
dc.publication.endPage | 985 | es |
dc.contributor.funder | Consejeria de Salud de la Junta de Andalucia | es |
dc.contributor.funder | Spanish Ministry of Economy, Innovation and Competition, Instituto de Salud Carlos III | es |